临床肾脏病杂志
臨床腎髒病雜誌
림상신장병잡지
JOURNAL OF CLINICAL NEPHROLOGY
2014年
10期
608-611
,共4页
傅博%谭静%祁爱蓉%韩晓苇
傅博%譚靜%祁愛蓉%韓曉葦
부박%담정%기애용%한효위
血液透析%慢性肾衰竭%现状调查%单中心研究
血液透析%慢性腎衰竭%現狀調查%單中心研究
혈액투석%만성신쇠갈%현상조사%단중심연구
Hemodialysis%Chronic renal failure%Current situation analysis%Single center study
目的:调查深圳市中医院维持性血液透析(maintenance hemodialysis,MHD)患者的现状。方法选择2013年3月至6月在本中心透析的147例 MHD 患者为研究对象,进行横断面调查,统计患者血管通路的种类和人数、每次透析的超滤情况,检测患者血红蛋白、血电解质、甲状旁腺素及透析前、透析后肾功能,并进行统计学分析,评价其透析状况。结果147例 MHD患者中,男女比例为1.58∶1,平均年龄(50.1±14.9)岁,原发病前2位分别为慢性肾小球肾炎和糖尿病肾脏疾病,血管通路以自体动静脉内瘘为主(140例,占95.23%);本组147例 MHD 患者中,配合采血者122例,采血依从性为82.99%;血红蛋白为(103.03±15.32)g/L,达到贫血治疗目标的患者有33例,达标率为27.04%,半数以上的患者存在轻度贫血;血钾为(5.32±0.79)mmol/L,高血钾症(>5.3 mmol/L)的患者49例(占40.16%);血钙为(2.15±0.22)mmol/L(未用血白蛋白校正),血磷(1.98±0.51)mmol/L,甲状旁腺素为359.2(163.35,825.2)ng/L(四分位分析法),贫血、血钾和钙磷代谢紊乱控制较差;透析充分性方面,尿素清除指数(Kt/V)值达标率为90.16%;乙型病毒性肝炎患者9例(占6.12%),无院内新增传染病患者。结论本中心患者大部分透析充分,传染病控制好,但部分患者慢性并发症控制欠佳,有待于加强对患者的管理和治疗。
目的:調查深圳市中醫院維持性血液透析(maintenance hemodialysis,MHD)患者的現狀。方法選擇2013年3月至6月在本中心透析的147例 MHD 患者為研究對象,進行橫斷麵調查,統計患者血管通路的種類和人數、每次透析的超濾情況,檢測患者血紅蛋白、血電解質、甲狀徬腺素及透析前、透析後腎功能,併進行統計學分析,評價其透析狀況。結果147例 MHD患者中,男女比例為1.58∶1,平均年齡(50.1±14.9)歲,原髮病前2位分彆為慢性腎小毬腎炎和糖尿病腎髒疾病,血管通路以自體動靜脈內瘺為主(140例,佔95.23%);本組147例 MHD 患者中,配閤採血者122例,採血依從性為82.99%;血紅蛋白為(103.03±15.32)g/L,達到貧血治療目標的患者有33例,達標率為27.04%,半數以上的患者存在輕度貧血;血鉀為(5.32±0.79)mmol/L,高血鉀癥(>5.3 mmol/L)的患者49例(佔40.16%);血鈣為(2.15±0.22)mmol/L(未用血白蛋白校正),血燐(1.98±0.51)mmol/L,甲狀徬腺素為359.2(163.35,825.2)ng/L(四分位分析法),貧血、血鉀和鈣燐代謝紊亂控製較差;透析充分性方麵,尿素清除指數(Kt/V)值達標率為90.16%;乙型病毒性肝炎患者9例(佔6.12%),無院內新增傳染病患者。結論本中心患者大部分透析充分,傳染病控製好,但部分患者慢性併髮癥控製欠佳,有待于加彊對患者的管理和治療。
목적:조사심수시중의원유지성혈액투석(maintenance hemodialysis,MHD)환자적현상。방법선택2013년3월지6월재본중심투석적147례 MHD 환자위연구대상,진행횡단면조사,통계환자혈관통로적충류화인수、매차투석적초려정황,검측환자혈홍단백、혈전해질、갑상방선소급투석전、투석후신공능,병진행통계학분석,평개기투석상황。결과147례 MHD환자중,남녀비례위1.58∶1,평균년령(50.1±14.9)세,원발병전2위분별위만성신소구신염화당뇨병신장질병,혈관통로이자체동정맥내루위주(140례,점95.23%);본조147례 MHD 환자중,배합채혈자122례,채혈의종성위82.99%;혈홍단백위(103.03±15.32)g/L,체도빈혈치료목표적환자유33례,체표솔위27.04%,반수이상적환자존재경도빈혈;혈갑위(5.32±0.79)mmol/L,고혈갑증(>5.3 mmol/L)적환자49례(점40.16%);혈개위(2.15±0.22)mmol/L(미용혈백단백교정),혈린(1.98±0.51)mmol/L,갑상방선소위359.2(163.35,825.2)ng/L(사분위분석법),빈혈、혈갑화개린대사문란공제교차;투석충분성방면,뇨소청제지수(Kt/V)치체표솔위90.16%;을형병독성간염환자9례(점6.12%),무원내신증전염병환자。결론본중심환자대부분투석충분,전염병공제호,단부분환자만성병발증공제흠가,유대우가강대환자적관리화치료。
Objective To investigate the current situation of maintenance hemodialysis (MHD) patients in Shenzhen Traditional Chinese Medicine Hospital.Methods We choose the MHD patients in our center from March to June 2013 as research objectives.A cross-sectional survey was done to statis-tically count the kind and number of the vascular access,and the ultrafiltration conditions were sur-veyed in each dialysis.Hemoglobin,blood electrolytes,intact parathyroid hormone and renal function before and after dialysis in MHD patients were detected.The results were statistically analyzed,and the current situations of the MHD patients evaluated.Results In 147 MHD patients,the ratio of men to women was 1.58∶1 and the average age was (50.1±14.9)years old.The first primary disease of MHD was chronic glomerulonephritis and the second was diabetic kidney disease.The main vascular access was autogenous arteriovenous fistula (95.23%).The blood collection compliance was 82.99%. The hemoglobin levels were (103.03±15.32)g/L,while the compliance rate of treatment of anemia was only 27.04%,suggesting that more than half of the patients had mild anemia.The serum potassi-um levels were (5.32±0.79)mmol/L,and there were 40.16% patients who had hyperkalemia.The serum calcium levels were (2.15±0.22)mmol/L (not corrected with serum albumin)and the serum phosphate levels were (1.98 ±0.51)mmol/L.The intact parathyroid hormone levels were 359.2 (163.35-825.2)ng/L.The control for anemia,high potassium,disorders of calcium and phosphorus metabolism was poor.The compliance rate of urea clearance index (Kt/V)was 90.16%.Hepatitis B patients accounted for 6.1%,and there was no new case of infection.Conclusions Most of the MHD patients in our center have adequate dialysis and have no new case of infection.But some chronic com-plications have been poor controlled.We should strengthen the management and treatment for the MHD patients.